Mesenchymal Stromal Cells: an Antimicrobial and Host-Directed Therapy for Complex Infectious Diseases-Reference-Cited by-同舟云学术

Mesenchymal Stromal Cells: an Antimicrobial and Host-Directed Therapy for Complex Infectious Diseases

Published:2021-12-15 Issue:4 Volume:34 Page:
ISSN:0893-8512
Container-title:Clinical Microbiology Reviews
language:en
Short-container-title:Clin Microbiol Rev

Author:

Shaw Timothy D.¹^ORCID,Krasnodembskaya Anna D.¹^ORCID,Schroeder Gunnar N.¹^ORCID,Zumla Alimuddin²^ORCID,Maeurer Markus³⁴^ORCID,O’Kane Cecilia M.¹^ORCID

Affiliation:

1. Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast, United Kingdom

2. Center for Clinical Microbiology, Division of Infection and Immunity, University College London, NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom

3. Immunosurgery Unit, Champalimaud Centre for the Unknown, Lisbon, Portugal

4. Department of Oncology and Haematology, Krankenhaus Nordwest, Frankfurt, Germany

Abstract

There is an urgent need for new antimicrobial strategies for treating complex infections and emerging pathogens. Human mesenchymal stromal cells (MSCs) are adult multipotent cells with antimicrobial properties, mediated through direct bactericidal activity and modulation of host innate and adaptive immune cells.

Funder

National Institute for Health Research

UKRI | Medical Research Council

Insmed

The Wellcome Trust

Bill and Melinda Gates Foundation

Department of Health, Northern Ireland

European and Developing Countries Clinical Trials Partnership

Fundação Champalimaud

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Microbiology (medical),Public Health, Environmental and Occupational Health,General Immunology and Microbiology,Epidemiology

Link

https://journals.asm.org/doi/pdf/10.1128/CMR.00064-21

Reference288 articles.

1. Antibacterial Resistance Leadership Group: Open for Business

2. World Health Organization. 2016. Global action plan on antimicrobial resistance. World Health Organization, Geneva, Switzerland. https://www.who.int/publications/i/item/9789241509763.

3. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects

4. Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis

5. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Umbilical cord mesenchymal stem cells: A powerful fighter against colon cancer?;Tissue and Cell;2024-10

2. Combinational therapy of mesenchymal stem cell-derived extracellular vesicles and azithromycin improves clinical and histopathological recovery in CLP sepsis model;International Immunopharmacology;2024-09

3. Anti-inflammatory and immunomodulatory effects of mesenchymal stem cell therapy on parasitic drug resistance;Expert Review of Anti-infective Therapy;2024-05-31

4. Advancing cell-based therapy in sepsis: An anesthesia outlook;Chinese Medical Journal;2024-05-06

5. MAC attack: MSCs and macrophages join forces against chronic lung infection;Thorax;2024-04-04